Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

Covid-19 diagnostics using a newly developed test – AUMED test RT-LAMP Assay SARS-CoV-2

kit aktuality

AUMED a.s. is involved in the fight against the Covid-19 pandemic. In cooperation with Protean s.r.o. and Institute of Molecular and Translational Medicine, AUMED a.s. launched a modern diagnostics of SARS-CoV-2 virus under the name AUMED test RT-LAMP Assay SARS-CoV-2. It is a diagnostic using the RT – LAMP Assay method. The test uses the so-called LAMP reaction, which is isothermal amplification of nucleic acids. Unlike the polymerase chain reaction (PCR, qPCR), in which the reaction is performed using temperature cycles, isothermal amplification is performed at a constant temperature so there is no require for any expensive equipment. The results are reliably read based on the color change with the naked eye.

The kit is fully validated. The functional evaluation was successfully performed by the Institute of Molecular and Translational Medicine in Olomouc. Comparison of the kit with the reference RT-PCR assay determined the sensitivity of the assay to be 93% and specificity to 99%. The kit passed all tested parameters and was recommended for use. We have fully prepared production capacity, mass production of the set has started. It is a completely Czech product without dependence on foreign suppliers.

Classical tests are time consuming. That is why we are coming to the market with the AUMED test RT-LAMP Assay SARS-CoV-2, which will facilitate the monitoring of infected people even in smaller or mobile laboratories.

You can find more about the benefits of this test here, or visit our new website dedicated to this test www.aumedtest.cz

MORE ARTICLES

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s